According to the meta-analysis, as shown by Figure 6, ICIs were as effective as chemotherapy in handling NSCLC patients with EGFR mutations for OS (HR, 1.11; 95% CI, (0.80, 1.53)). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.